A clinical-stage biotechnology company developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection | Business Wire
https://t.co/JKkM5lkDlF
GenSight Biologics invite Julien Secheyron, « Patient N°15 » de la 1ère étude clinique de LUMEVOQ®, à venir présenter son livre « Vous ne verrez plus »
https://t.co/RGGfiuOsww
GenSight Biologics reports second patient case showing significant visual recovery after GS030 optogenetic treatment in the PIONEER Phase I/II trial
Patient video on https://t.co/wYGhbzvbrn
#Optogenetics#Ophthalmology#retinitis#blindness#AAO2021
GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022 | Business Wire
https://t.co/uNZzGSibgL
Investigators conducted an optogenetics vision restoration in a man with retinitis pigmentosa who had been blind for decades — here's what they've found: https://t.co/emkWEzgCDn
@UPMC@UniBasel_en@GenSightBio#Ophthalmology#GeneTherapy
@US_FDA has granted Fast Track Designation to GS030, which combines AAV2-based #genetherapy with #optogenetics to treat #retinitispigmentosa
It highlights the significant unmet need for a safe and effective treatment of all forms of RP @bernard_gilly
https://t.co/MFnoSiF9wI
La start-up française @GenSightBio a mis au point une thérapie génique qui redonne leur autonomie aux patients atteints de la maladie de Leber, qui rend quasi-aveugle en quelques semaines https://t.co/aRTNu9v7lL récit par @domnora
Investigators conducted an optogenetics vision restoration in a man with retinitis pigmentosa who had been blind for decades — here's what they've found: https://t.co/1K9Dzf7eUQ
@UPMC@UniBasel_en@GenSightBio#Ophthalmology#GeneTherapy
@GenSightBio announces that the peer reviewed journal International Ophthalmology Clinics has published a review of all current and past gene therapy trials for LHON. To read more, go to https://t.co/jAfkvEW3p7 #Clinicaltrials#LHON
Just published in the peer-reviewed International Ophthalmology Clinics
- Bilateral treatment effect following unilateral injection of #genetherapy independently reported by three research groups
- LUMEVOQ® for #LHON first #genetherapy requesting #maa#EMA
https://t.co/94TN74k4f6
Investigators conducted an optogenetics vision restoration in a man with retinitis pigmentosa who had been blind for decades — here's what they've found: https://t.co/wNoehqpA6H
@UPMC@UniBasel_en@GenSightBio#Ophthalmology#GeneTherapy
Investigators conducted an optogenetics vision restoration in a man with retinitis pigmentosa who had been blind for decades — here's what they've found: https://t.co/MwKrgTGrze
@UPMC@UniBasel_en@GenSightBio#Ophthalmology#GeneTherapy